Author

J. Digiovanni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Balmain· 1 shared A. U. Schirmer· 1 shared B. J. Eduful· 1 shared C. I. Wells· 1 shared D. Drewry· 1 shared D. Wu· 1 shared E. Kandyba· 1 shared E. Macias· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Balmain

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The interplay between dormant mutated cells and tumor promotion by chronic tissue damage in determining cancer risk.

Y. R. Li, E. Kandyba, K. Halliwill, R. Delrosario, Q. Tran, N. Bayani, D. Wu, O. Mirzoeva, M. M. Reeves, M. Islam, L. Riva, E. N. Bergstrom, K. Achanta, J. Digiovanni, L. Alexandrov, A. Balmain

This study analyzes mouse skin tumors to determine how environmental factors like TPA, obesity, and wounding affect mutational burden and cancer risk, finding that tumor promoters, not mutation number, limit tumor growth.

bioRxiv · Jan 24, 2024 · PreprintCancer Biology

Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer

A. U. Schirmer, L. M. Driver, M. T. Zhao, C. I. Wells, J. E. Pickett, S. N. O'Bryne, B. J. Eduful, X. Yang, L. Howard, S. You, G. R. Devi, J. Digiovanni, S. F. Freedland, J.-T. A. Chi, D. Drewry, E. Macias

This study shows that STK3, typically a tumor suppressor, promotes prostate cancer growth and identifies STK3 inhibitors with therapeutic potential.

bioRxiv · Feb 21, 2021Cancer Biology